Aug 14 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.13.AS OF JUNE 30, 2019, CASH AND CASH EQUIVALENTS TOTALED APPROXIMATELY $12.8 MILLION.
Full Article
July 31 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS ADVANCES GALINPEPIMUT-S (GPS) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) PROGRAM WITH DOSING OF FIRST PATIENT IN PHASE 1/2 BASKET STUDY.SELLAS LIFE SCIENCES GROUP INC - FIRST CLINICAL DATA EXPECTED IN Q1 OF 2020.SELLAS LIFE SCIENCES GROUP INC - STUDY IS BEING CONDUCTED WITH MERCK UNDER A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT.SELLAS LIFE SCIENCES GROUP INC - TRIAL TO ENROLL PATIENTS WITH OVARIAN, COLORECTAL, TRIPLE NEGATIVE BREAST, AND SMALL CELL LUNG CANCERS.
Full Article
June 14 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES PRICING OF $15 MILLION PUBLIC OFFERING.SELLAS LIFE SCIENCES GROUP INC - SHARES OF COMMON STOCK AND ACCOMPANYING COMMON WARRANTS AT A COMBINED PUBLIC OFFERING PRICE OF $0.15 PER SHARE..SELLAS LIFE SCIENCES GROUP INC - COMMON WARRANTS WILL HAVE AN EXERCISE PRICE OF $0.50 PER SHARE.SELLAS LIFE SCIENCES GROUP INC - OFFERING 26.4 MILLION SHARES TOGETHER WITH COMMON STOCK WARRANTS.
Full Article
June 6 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP FILES FOR OFFERING OF 33.9 MILLION COMMON SHARES AND WARRANTS TO PURCHASE UP TO 33.9 MILLION COMMON SHARES - SEC FILING.
Full Article
May 31 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC - GOT NOTIFICATION FROM NASDAQ STOCK MARKET LLC INDICATING THAT CO WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE.
Full Article
May 23 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP FILES FOR OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS TO BUY SHARES OF COMMON STOCK OF UP TO $23.0 MILLION - SEC FILING.
Full Article
May 15 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.22.AS OF MARCH 31, 2019, CASH AND CASH EQUIVALENTS TOTALED APPROXIMATELY $2.6 MILLION.AS OF MARCH 31, 2019, CASH AND CASH EQUIVALENTS TOTALED APPROXIMATELY $2.6 MILLION..
Full Article
Nov 15 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.53.QTRLY EARNINGS PER SHARE $0.53.SELLAS LIFE SCIENCES GROUP - AS OF SEPT 30, 2018, UNRESTRICTED CASH AND CASH EQUIVALENTS TOTALED $10.0 MILLION.
Full Article
Nov 9 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES SETTLEMENT OF COUNTERCLAIMS AGAINST JGB (CAYMAN) NEWTON, LTD. FOR $6.6 MILLION PAYMENT BY JGB.SELLAS LIFE SCIENCES GROUP INC - DEBENTURE AND ALL SECURITY INTERESTS HELD BY JGB TERMINATED.SELLAS LIFE SCIENCES - JGB HAS PAID CO ABOUT $6.6 MILLION IN EXCHANGE FOR DISCHARGE OF CLAIMS & COUNTERCLAIMS ASSERTED BY CO & JGB IN LITIGATION.
Full Article
May 23 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING.
Full Article
Earnings vs. 
Estimates